SI2369005T1 - Biological active proteins having increased in vivo and/or in vitro stability - Google Patents

Biological active proteins having increased in vivo and/or in vitro stability

Info

Publication number
SI2369005T1
SI2369005T1 SI200830978T SI200830978T SI2369005T1 SI 2369005 T1 SI2369005 T1 SI 2369005T1 SI 200830978 T SI200830978 T SI 200830978T SI 200830978 T SI200830978 T SI 200830978T SI 2369005 T1 SI2369005 T1 SI 2369005T1
Authority
SI
Slovenia
Prior art keywords
active proteins
biologically active
vivo
increased
amino acid
Prior art date
Application number
SI200830978T
Other languages
Slovenian (sl)
Inventor
Arne Skerra
Ina Theobald
Martin Schlapschy
Original Assignee
Technische Universitet Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39776993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2369005(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Technische Universitet Muenchen filed Critical Technische Universitet Muenchen
Publication of SI2369005T1 publication Critical patent/SI2369005T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Abstract

The present invention relates to biologically active proteins comprising at least two domains wherein a first domain of said at least two domains comprises an amino acid sequence having and/or mediating said biological activity and a second domain of said at least two domains comprises an amino acid sequence consisting preferably of at least about 100 amino acid residues forming a random coil conformation whereby said random coil conformation mediates an increased in vivo and/or in vitro stability of said biologically active protein. Furthermore, nucleic acid molecules encoding the inventive biologically active proteins and vectors and cells comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions comprising the compounds of the invention as well as for specific uses of the biologically active proteins, nucleic acid molecules, vectors and cells of the invention.
SI200830978T 2007-06-21 2008-06-20 Biological active proteins having increased in vivo and/or in vitro stability SI2369005T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07012219 2007-06-21
US7170508P 2008-05-14 2008-05-14
EP11158295A EP2369005B1 (en) 2007-06-21 2008-06-20 Biological active proteins having increased in vivo and/or in vitro stability

Publications (1)

Publication Number Publication Date
SI2369005T1 true SI2369005T1 (en) 2013-09-30

Family

ID=39776993

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200830978T SI2369005T1 (en) 2007-06-21 2008-06-20 Biological active proteins having increased in vivo and/or in vitro stability
SI200830250T SI2173890T1 (en) 2007-06-21 2008-06-20 Biological active proteins having increased in vivo and/or vitro stability

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200830250T SI2173890T1 (en) 2007-06-21 2008-06-20 Biological active proteins having increased in vivo and/or vitro stability

Country Status (20)

Country Link
US (2) US8563521B2 (en)
EP (2) EP2173890B1 (en)
JP (1) JP5351889B2 (en)
KR (2) KR101701080B1 (en)
CN (1) CN101970678B (en)
AT (1) ATE502114T1 (en)
AU (1) AU2008266448B2 (en)
CA (1) CA2691386C (en)
CY (1) CY1111491T1 (en)
DE (1) DE602008005596D1 (en)
DK (2) DK2369005T3 (en)
EA (1) EA021222B8 (en)
ES (2) ES2422007T3 (en)
HK (1) HK1156980A1 (en)
HR (1) HRP20110368T1 (en)
NZ (1) NZ580670A (en)
PL (2) PL2173890T3 (en)
PT (1) PT2173890E (en)
SI (2) SI2369005T1 (en)
WO (1) WO2008155134A1 (en)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
ES2385114T3 (en) 2007-03-30 2012-07-18 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
JP2010536341A (en) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド Compositions and methods for altering properties of biologically active polypeptides
AU2009246142A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
CN102131516B (en) 2008-06-27 2016-03-16 杜克大学 Comprise the therapeutic agent of elastin-like peptides
NZ593833A (en) 2009-02-03 2013-10-25 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8957021B2 (en) * 2009-02-03 2015-02-17 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
CN106916229A (en) * 2009-06-08 2017-07-04 阿穆尼克斯运营公司 Growth hormone polypeptides and its preparation and application
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP3222287A1 (en) * 2009-08-24 2017-09-27 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
LT2531206T (en) 2010-02-04 2017-09-25 Morphotek, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
WO2011123813A2 (en) * 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR081361A1 (en) 2010-04-30 2012-08-29 Molecular Partners Ag MODIFIED UNION PROTEINS THAT INHIBIT THE RECEPTOR INTERACTION OF THE VASCULAR ENDOTELIAL GROWTH FACTOR FROM GLICOPROTEIN TO VEGF-A
ES2811065T3 (en) 2010-05-11 2021-03-10 Hutchinson Fred Cancer Res Chlorotoxin variants, conjugates and methods for their use
SI2571510T1 (en) 2010-05-21 2019-02-28 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
BR112012029611A2 (en) 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc bispecific fusion protein, pharmaceutical composition, method of treating tissue damage in an individual, method of promoting tissue regeneration or survival in an individual, and nucleic acid molecule
CA2802635A1 (en) 2010-06-18 2011-12-22 Xiberscience Gmbh Peptides as active agents to stabilize biologic barriers
CA2806438C (en) 2010-07-29 2021-04-13 Eleven Biotherapeutics, Inc. Chimeric il-1 receptor type i agonists and antagonists
EP2643349B1 (en) 2010-11-26 2019-09-04 Molecular Partners AG Designed repeat proteins binding to serum albumin
IL210093A0 (en) 2010-12-19 2011-06-30 David Helman Membrane bound reporter molecules and their use in cell sorting
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
EP3527218A1 (en) 2011-06-10 2019-08-21 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
PT3513804T (en) 2011-07-08 2022-06-02 Bioverativ Therapeutics Inc Factor viii chimeric and hybrid polypeptides, and methods of use thereof
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
WO2013019652A1 (en) 2011-07-29 2013-02-07 Eleven Biotherapeutics, Inc. Purified proteins
WO2013024049A1 (en) * 2011-08-12 2013-02-21 Ascendis Pharma A/S Protein carrier-linked prodrugs
IN2014CN00989A (en) 2011-08-12 2015-04-10 Ascendis Pharma As
LT2804623T (en) 2012-01-12 2019-12-10 Bioverativ Therapeutics Inc Chimeric factor viii polypeptides and uses thereof
US20130210747A1 (en) 2012-02-13 2013-08-15 University Of Southern California Methods and Therapeutics Comprising Ligand-Targeted ELPs
ES2771208T3 (en) 2012-02-15 2020-07-06 Bioverativ Therapeutics Inc Factor VIII compositions and methods of preparation and use thereof
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
MX366864B (en) 2012-02-27 2019-07-26 Amunix Operating Inc Xten conjugate compositions and methods of making same.
EP3646880A1 (en) 2012-05-07 2020-05-06 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc Chimeric clotting factors
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
EA201792485A3 (en) 2012-07-11 2019-03-29 Амуникс Оперэйтинг Инк. COMPLEX OF FACTOR VIII WITH XTEN AND PROTEIN FACTOR VILLEBRAND VON AND ITS APPLICATION (OPTIONS)
WO2014026054A2 (en) 2012-08-10 2014-02-13 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
US20140092376A1 (en) * 2012-10-01 2014-04-03 Momentive Performance Materials, Inc. Container and method for in-line analysis of protein compositions
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) 2012-10-30 2016-04-20 Biogen Ma Inc Methods of using fviii polypeptide
WO2014081849A1 (en) 2012-11-20 2014-05-30 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
EP2928913A1 (en) 2012-12-10 2015-10-14 Fred Hutchinson Cancer Research Center Lipocalin fusion partners
TWI617574B (en) 2012-12-11 2018-03-11 梅迪繆思有限公司 Glucagon and glp-1 co-agonists for the treatment of obesity
LT3889173T (en) 2013-02-15 2023-10-10 Bioverativ Therapeutics Inc. Optimized factor viii gene
JP6450364B2 (en) 2013-03-13 2019-01-09 セセン バイオ， インコーポレイテッド Chimeric cytokine formulations for ocular delivery
AU2014230472A1 (en) 2013-03-14 2015-10-01 Medimmune Limited Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
EP2968477B1 (en) 2013-03-15 2019-12-04 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
JP6387392B2 (en) 2013-03-15 2018-09-05 バイオベラティブ セラピューティクス インコーポレイテッド Factor IX polypeptide preparation
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US20160311885A1 (en) 2013-08-14 2016-10-27 Biogen Ma Inc. Recombinant factor viii proteins
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
PL3065761T3 (en) 2013-11-05 2020-05-18 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
CA2929201A1 (en) 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
DE102013113156A1 (en) 2013-11-28 2015-05-28 Freie Universität Berlin A compound and method for selectively radiolabeling polypeptides by solid phase synthesis
EP4332839A2 (en) 2013-12-06 2024-03-06 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP3102224B1 (en) * 2013-12-20 2019-02-20 NephroGenesis, LLC. Apparatuses for kidney dialysis and lipocalin protein for use in the prevention or treatment of uremia by dialysis
IL246476B (en) 2014-01-10 2022-06-01 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
US9975929B2 (en) 2014-03-05 2018-05-22 Merz Pharma Gmbh & Co. Kgaa Recombinant clostridial neurotoxins with increased duration of effect
SG10201808249VA (en) 2014-03-24 2018-10-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations
EP2937096B1 (en) 2014-04-23 2019-08-21 Julius-Maximilians-Universität Würzburg Peptides derived from RS1 which down-regulate glucose absorption after a glucose rich meal and increase insulin sensitivity
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CR20170110A (en) 2014-09-26 2017-05-08 Bayer Pharma AG STABILIZED DERIVATIVES OF ADRENOMEDULINE AND USE OF THE SAME
ES2665218T3 (en) 2014-09-30 2018-04-24 Thena Biotech S.r.l. A fusion protein, a nanoparticle composed of a plurality of monomers of said fusion protein and uses thereof
ES2753391T3 (en) 2014-10-14 2020-04-08 Halozyme Inc Adenosine deaminase 2 (ADA2) compositions, variants thereof and methods of use thereof
CN107208076A (en) 2014-10-17 2017-09-26 科达制药 Butyrylcholine esterase amphoteric ion polymer conjugate
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
PE20170950A1 (en) 2014-10-24 2017-07-13 Bristol Myers Squibb Co MODIFIED FIBROBLAST GROWTH FACTOR 2 (FGF-21) POLYEPTIDES AND USES OF THE SAME
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
US10722590B2 (en) 2014-11-21 2020-07-28 Phasebio Pharmaceuticals, Inc. ELP fusion proteins for controlled and sustained release
WO2016079302A1 (en) 2014-11-21 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Long-acting growth hormone dosage forms
US20160168228A1 (en) 2014-12-10 2016-06-16 S-Aima Holding Company, Llc Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
WO2016130518A2 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
WO2016145237A1 (en) * 2015-03-11 2016-09-15 Yu Fu-Shin X Composition and methods to promote wound healing
ES2953482T3 (en) 2015-04-02 2023-11-13 Molecular Partners Ag Ankyrin repeat domains designed with binding specificity for serum albumin
TWI726889B (en) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 Protease-resistant lipidated peptides
TW201718627A (en) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 Recombinant clostridial neurotoxin, a use thereof, and a method for generating the same, a pharmaceutical composition comprising the same and a precursor corresponding to the same, a nucleic acid sequence encoding the precursor and a method for obtaining
KR20180029262A (en) 2015-08-03 2018-03-20 바이오버라티브 테라퓨틱스 인크. Factor IX fusion proteins and methods for their manufacture and use
EP4129327A1 (en) 2015-08-28 2023-02-08 Amunix Pharmaceuticals, Inc. Chimeric polypeptide assembly and methods of making and using the same
ES2863278T3 (en) 2015-10-02 2021-10-11 Silver Creek Pharmaceuticals Inc Bispecific therapeutic proteins for tissue repair
WO2017083491A2 (en) * 2015-11-10 2017-05-18 Proteothera, Inc. Methods of producing and purifying matrix-binding fusion proteins by ion-exchange chromatography
EP3394266B1 (en) * 2015-12-22 2021-04-14 XL-protein GmbH Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
EP3397276A4 (en) 2015-12-30 2019-12-18 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2017118707A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
DK3400019T3 (en) 2016-01-08 2022-10-24 Ascendis Pharma Growth Disorders As CNP prodrugs with carrier attachment at the ring unit
NZ743487A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
CA3007976C (en) 2016-01-08 2023-09-26 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
EP3400022A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
AU2017205694B2 (en) 2016-01-08 2022-05-26 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
ES2929347T3 (en) * 2016-01-20 2022-11-28 Merz Pharma Gmbh & Co Kgaa Novel recombinant clostridial neurotoxins with increased duration of effect
AU2017214378B2 (en) 2016-02-01 2023-05-04 Bioverativ Therapeutics Inc. Optimized Factor VIII genes
EP3423103A1 (en) 2016-03-01 2019-01-09 Ascendis Pharma Bone Diseases A/S Pth prodrugs
KR102460198B1 (en) 2016-03-10 2022-10-31 메디뮨 리미티드 Glucagon and GLP-1 co-agonists for the treatment of obesity
AU2017260274A1 (en) * 2016-05-04 2018-11-01 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
KR102449167B1 (en) 2016-05-06 2022-09-28 파세비오 파마수티컬스 인코포레이티드 ELP fusion protein for controlled sustained release
US11896671B2 (en) 2016-07-13 2024-02-13 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
JP7085535B2 (en) 2016-09-29 2022-06-16 アセンディス ファーマ ボーン ディジージズ エー／エス PTH compounds with a small peak-to-trough ratio
CA3037444A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release pth compounds
LT3518960T (en) 2016-09-29 2023-09-11 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
SI3518930T1 (en) 2016-09-29 2023-06-30 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release cnp agonists
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
EP3548063A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MA47163A (en) 2016-12-16 2019-11-06 Biogen Ma Inc PROTEOLYTICALLY STABILIZED ACTIVATED GROWTH DIFFERENTIATION FACTOR 11
MX2019009063A (en) 2017-01-31 2019-10-21 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same.
EP3596115A1 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
WO2018170026A2 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
HRP20231382T1 (en) 2017-03-16 2024-02-16 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
PL3612208T3 (en) 2017-04-21 2023-07-24 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of autoimmune blistering diseases
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
KR20200030065A (en) 2017-06-21 2020-03-19 재즈 파마슈티칼즈 아일랜드 리미티드 Modified L-asparaginase
JP7224650B2 (en) * 2017-06-21 2023-02-20 エクスエル‐プロテイン ゲーエムベーハー Conjugates of protein drugs and P/A peptides
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
TW201920255A (en) 2017-08-09 2019-06-01 美商生物化學醫療公司 Nucleic acid molecules and uses thereof
AU2018351000B2 (en) 2017-10-18 2023-11-30 Alpine Immune Sciences, Inc. Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
PT3707261T (en) * 2017-11-06 2022-07-13 Thena Biotech S R L Fusion-proteins based on human ferritin and protease-cleavable peptides and their use as chemotherapeutics carriers
EP3483619A1 (en) * 2017-11-13 2019-05-15 Technische Universität München Automated noninvasive determining the sex of an embryo of and the fertility of a bird's egg
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
BR112020015228A2 (en) 2018-02-01 2020-12-29 Bioverativ Therapeutics Inc. USE OF LENTIVIRAL VECTORS THAT EXPRESS FACTOR VIII
GB201804092D0 (en) * 2018-03-14 2018-04-25 Imperial Innovations Ltd Methods and compositions
KR20200139730A (en) 2018-03-28 2020-12-14 아센디스 파마 온콜로지 디비전 에이/에스 IL-2 conjugate
CA3093083A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
EP3774861A1 (en) 2018-03-28 2021-02-17 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
KR20210020030A (en) 2018-05-18 2021-02-23 바이오버라티브 테라퓨틱스 인크. How to treat hemophilia A
AU2019270464A1 (en) 2018-05-18 2020-11-19 Ascendis Pharma Bone Diseases A/S Starting dose of PTH conjugates
US20210363219A1 (en) 2018-06-15 2021-11-25 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
BR112020026512A2 (en) 2018-07-03 2021-04-06 Bristol-Myers Squibb Company FGF-21 FORMULATIONS
MX2021001599A (en) 2018-08-09 2021-07-02 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof for non-viral gene therapy.
EP3849588A1 (en) 2018-09-10 2021-07-21 Volution Immuno Pharmaceuticals SA Coversin for use in the treatment of rheumatic diseases
BR112021005907A2 (en) 2018-09-27 2021-08-10 Xilio Development, Inc. masked cytokines, nucleic acid, vector, host cell, methods for producing a masked cytokine, for treating or preventing a neoplastic disease and for treating or preventing a neoplastic inflammatory or autoimmune disease, composition, pharmaceutical composition and kit
CN111040021B (en) * 2018-10-12 2023-06-02 浙江道尔生物科技有限公司 Carrier protein for improving bioactive protein property
JP2022013959A (en) * 2018-11-02 2022-01-19 味の素株式会社 Fusion protein
CN111153965A (en) * 2018-11-07 2020-05-15 浙江道尔生物科技有限公司 Artificial recombinant protein for improving performance of active protein or polypeptide and application thereof
US20220025344A1 (en) 2018-11-26 2022-01-27 Novartis Ag Lpl-gpihbp1 fusion polypeptides
JP2022510276A (en) 2018-11-30 2022-01-26 アルパイン イミューン サイエンシズ インコーポレイテッド CD86 variant immunomodulatory protein and its use
EP3891289A2 (en) 2018-12-06 2021-10-13 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor ix
JP2022520189A (en) 2019-02-11 2022-03-29 アセンディス ファーマ ボーン ディジージズ エー／エス Liquid pharmaceutical formulation of PTH conjugate
AU2020223441A1 (en) 2019-02-11 2021-07-29 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of CNP conjugates
CN113573698A (en) 2019-03-04 2021-10-29 阿森迪斯药物内分泌股份有限公司 Long-acting growth hormone dosage form having superior efficacy compared to daily growth hormone
CN114008069A (en) 2019-04-17 2022-02-01 科迪亚克生物科学公司 Compositions of exosomes and AAV
GB201905810D0 (en) 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
CN114174326A (en) 2019-06-18 2022-03-11 拜耳公司 Long-term stable adrenomedullin analogues and uses thereof
AU2020296297A1 (en) 2019-06-21 2021-12-16 Ascendis Pharma A/S Conjugates of heteroaromatic nitrogen-comprising compounds
CA3143435A1 (en) 2019-06-21 2020-12-24 Nicola BISEK Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
US20230065814A1 (en) 2019-06-21 2023-03-02 Ascendis Pharma A/S Conjugates of-electron-pair-donating heteroaromatic nitrogen-comprising compounds
US20220281939A1 (en) 2019-08-27 2022-09-08 Tonix Pharma Limited Modified tff2 polypeptides
WO2021058117A1 (en) 2019-09-27 2021-04-01 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (hsct-tma)
TW202126284A (en) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 Lentiviral vector formulations
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113597434B (en) 2019-12-31 2022-07-01 北京质肽生物医药科技有限公司 Fusion proteins of GLP-1 and GDF15 and conjugates thereof
CN115175738A (en) 2020-01-03 2022-10-11 阿森迪斯药物股份有限公司 Conjugates undergoing intramolecular rearrangement
CN115322794A (en) 2020-01-11 2022-11-11 北京质肽生物医药科技有限公司 Conjugates of fusion proteins of GLP-1 and FGF21
KR20220128390A (en) 2020-01-13 2022-09-20 아센디스 파마 본 디지즈 에이/에스 Treatment of hypoparathyroidism
WO2021226553A2 (en) 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
EP4161956A1 (en) 2020-06-03 2023-04-12 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
CA3184998A1 (en) 2020-08-05 2022-02-10 Samuel WEISBROD Conjugates comprising reversible linkers and uses thereof
WO2022032187A1 (en) 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
IL300668A (en) 2020-08-28 2023-04-01 Ascendis Pharma Oncology Div A/S Glycosylated il-2 proteins and uses thereof
TW202228784A (en) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 Compound for the sequestration of undesirale anti-peg antibodies in a patient
MX2023003540A (en) 2020-09-28 2023-04-21 Ascendis Pharma Bone Diseases As Improvement of physical and mental well-being of patients with hypoparathyroidism.
JP2023545684A (en) 2020-09-30 2023-10-31 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド Polypeptide conjugates and methods of use
WO2022115597A1 (en) 2020-11-25 2022-06-02 Bristol-Myers Squibb Company Methods of treating liver diseases
EP4259199A1 (en) 2020-12-11 2023-10-18 Friedrich Miescher Institute for Biomedical Research Hdac6 binding proteins and their anti-viral use
WO2022136582A1 (en) 2020-12-22 2022-06-30 Xl-Protein Gmbh Antibodies specific for structurally disordered sequences
IL307192A (en) 2021-04-01 2023-11-01 Ascendis Pharma As Use of long-acting growth hormone for treating inflammation-induced diseases
TW202313974A (en) 2021-06-08 2023-04-01 瑞典商阿斯特捷利康公司 Combination therapies for treatment of liver diseases
CA3229668A1 (en) 2021-08-23 2023-03-02 Bioverativ Therapeutics Inc. Baculovirus expression system
CA3230895A1 (en) 2021-09-22 2023-03-30 Kennett Sprogoe Long-acting pth compound treatments
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
WO2023227505A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
EP4342460A1 (en) 2022-09-21 2024-03-27 NovoArc GmbH Lipid nanoparticle with nucleic acid cargo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI92601C (en) * 1992-03-11 1994-12-12 Marja Makarow Procedure for secretion of yeast beneficial proteins
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
EP1299535A2 (en) 2000-06-30 2003-04-09 Maxygen Aps Peptide extended glycosylated polypeptides
JP5735194B2 (en) 2005-01-25 2015-06-17 セル セラピューティクス インコーポレーテッド Biologically active protein with improved in vivo half-life
KR101312339B1 (en) * 2005-04-20 2013-09-27 주식회사 바이로메드 Compositions and methods for fusion protein separation
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
DK2402754T4 (en) 2006-03-06 2023-08-28 Amunix Operating Inc Unstructured recombinant polymers and uses thereof
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
NZ593833A (en) 2009-02-03 2013-10-25 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same

Also Published As

Publication number Publication date
JP2010531139A (en) 2010-09-24
CN101970678A (en) 2011-02-09
DK2369005T3 (en) 2013-06-24
WO2008155134A1 (en) 2008-12-24
US20100292130A1 (en) 2010-11-18
KR20150092355A (en) 2015-08-12
AU2008266448A1 (en) 2008-12-24
ES2422007T3 (en) 2013-09-06
EP2369005A1 (en) 2011-09-28
EP2369005B1 (en) 2013-04-03
PL2173890T3 (en) 2011-07-29
US8563521B2 (en) 2013-10-22
NZ580670A (en) 2011-09-30
EP2173890B1 (en) 2011-03-16
HRP20110368T1 (en) 2011-06-30
EA021222B1 (en) 2015-05-29
ATE502114T1 (en) 2011-04-15
ES2362386T3 (en) 2011-07-04
KR101631323B1 (en) 2016-06-17
SI2173890T1 (en) 2011-06-30
JP5351889B2 (en) 2013-11-27
KR101701080B1 (en) 2017-01-31
DK2173890T3 (en) 2011-06-27
CA2691386A1 (en) 2008-12-24
EA021222B8 (en) 2015-11-30
HK1156980A1 (en) 2012-06-22
CY1111491T1 (en) 2015-08-05
EP2173890A1 (en) 2010-04-14
US20140050693A1 (en) 2014-02-20
KR20100044732A (en) 2010-04-30
PL2369005T3 (en) 2013-10-31
CN101970678B (en) 2014-08-20
US9260494B2 (en) 2016-02-16
CA2691386C (en) 2014-12-23
AU2008266448B2 (en) 2013-06-13
PT2173890E (en) 2011-05-06
DE602008005596D1 (en) 2011-04-28
EA201000040A1 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
HK1156980A1 (en) Biological active proteins having increased in vivo and or vitro stability
MX338914B (en) Biosynthetic proline/alanine random coil polypeptides and their uses.
MX2009002816A (en) Albumin fusion proteins.
WO2007021494A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
WO2005077042A3 (en) Albumin fusion proteins
WO2005003296A3 (en) Albumin fusion proteins
DK2343320T3 (en) ANTI-GITR ANTIBODIES AND APPLICATIONS THEREOF
ATE483027T1 (en) RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROKARYONTIC CELLS
CY1113684T1 (en) ANTI-MICROBIAKA CONTAINERS CONTAINING AN ARGININE - KAI / OR LYSINE - CONTAINING A MOBILE
WO2008061208A3 (en) Arylsulfonamide compounds
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
EP3338790A3 (en) Oligopeptidic compounds and uses thereof
WO2008052173A3 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2009004315A8 (en) Isolated peptides and uses thereof
WO2007010080A3 (en) Novel carbosilane dendrimers, preparation method thereof and use of same
PL1791858T3 (en) Modified vp1-capsid protein of parvovirus b19
WO2007093848A3 (en) Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
DE602005025141D1 (en) Cell-penetrating peptides as carriers for molecules
WO2008003707A3 (en) Minimized small peptides with high affinity for factor viii and factor viii-like proteins
EP1896588A4 (en) NOVEL Aß-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF
EP1885867A4 (en) Novel methods
WO2009148955A3 (en) Multi-arm amines and uses thereof
WO2003055528A3 (en) Amphiphilic compounds for pharmaceutical or cosmetic use
WO2004081165A3 (en) Novel purified dihydrodipicolinate synthase polypeptides and structures thereof